Showing 5041-5060 of 8875 for: Cochrane Systematic Reviews Back
- Methotrexate for ankylosing spondylitis
Cochrane Systematic Reviews, 28-Feb-2013
Ankylosing spondylitis (AS) is a chronic inflammatory disease of unknown cause, characterized by sacroiliitis and spondylitis. Methotrexate (MTX), a widely used disease-modifying antirheumatic drug (DMARD), is effective for rheumatoid arthritis (RA), and
- Methotrexate for high‐grade osteosarcoma in children and young adults
Cochrane Systematic Reviews, 11-May-2011
The majority of the currently used treatment protocols for osteosarcoma are based on a combination of doxorubicin, cisplatin, methotrexate (MTX) and/or ifosfamide, of which MTX seems to be one of the most active drugs. However, in the literature, this has
- Methotrexate for induction of remission in refractory Crohn's disease
Cochrane Systematic Reviews, 6-Aug-2014
Although corticosteroids are effective for induction of remission of Crohn's disease, many patients relapse when steroids are withdrawn or become steroid dependent. Furthermore, corticosteroids exhibit significant adverse effects. The success of methotrex
- Methotrexate for induction of remission in ulcerative colitis
Cochrane Systematic Reviews, 3-Oct-2014
Ulcerative colitis (UC) is a chronic inflammatory bowel disease. Corticosteroids and 5-aminosalicylates are the most commonly used therapies. However, many patients require immunosuppressive therapy for steroid-refractory and steroid-dependent disease. Me
- Methotrexate for maintenance of remission in Crohn's disease
Cochrane Systematic Reviews, 23-Aug-2014
Safe and effective long-term treatments that reduce the need for corticosteroids are needed for Crohn's disease. Although purine antimetabolites are moderately effective for maintenance of remission patients often relapse despite treatment with these agen
- Methotrexate for maintenance of remission in ulcerative colitis
Cochrane Systematic Reviews, 11-Aug-2015
Methotrexate, a folate antagonist, is an immunosuppressant drug that is effective for treating several inflammatory disorders including Crohn's disease. Ulcerative colitis, a related chronic inflammatory bowel disease, can be challenging to treat. T his u
- Methotrexate for multiple sclerosis
Cochrane Systematic Reviews, 5-Sep-2010
Methotrexate is a potent immunosuppressant which in theory could reduce relapse rates and delay disease progression in multiple sclerosis (MS). Subsequently, clinical trials of methotrexate have been conducted in people with MS.
- Methotrexate for primary biliary cirrhosis
Cochrane Systematic Reviews, 12-May-2010
Methotrexate has been used to treat patients with primary biliary cirrhosis as it possesses immunosuppressive properties. The previously prepared version of this review from 2005 showed that methotrexate seemed to significantly increase mortality in patie
- Methotrexate for psoriatic arthritis
Cochrane Systematic Reviews, 21-Jan-2019
Psoriatic arthritis is an inflammatory disease associated with joint damage, impaired function, pain, and reduced quality of life. Methotrexate is a disease-modifying anti-rheumatic drug (DMARD) commonly prescribed to alleviate symptoms, attenuate disease
- Methotrexate for treating juvenile idiopathic arthritis
Cochrane Systematic Reviews, 23-Oct-2001
In both adult rheumatoid arthritis (RA) and juvenile arthritis, the focus has shifted from 'inflammation parameters' to more patient centered disability outcomes. In RA this resulted in the development of the Outcome Measures in Arthritis Clinical Trials
- Methotrexate for treating rheumatoid arthritis
Cochrane Systematic Reviews, 10-Jun-2014
Methotrexate is a folic acid antagonist widely used for the treatment of neoplastic disorders. Methotrexate inhibits the synthesis of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins by binding to dihydrofolate reductase. Currently, methot
- Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis: A network meta‐analysis
Cochrane Systematic Reviews, 29-Aug-2016
Methotrexate is considered the preferred disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis, but controversy exists on the additional benefits and harms of combining methotrexate with other DMARDs.
- Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis
Cochrane Systematic Reviews, 14-Apr-2010
Methotrexate (MTX) is among the most effective disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) with less toxicity and better tolerability.
- Methyldopa for primary hypertension
Cochrane Systematic Reviews, 7-Oct-2009
Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive heart failure. Methyldopa is a centrally acting antihypertensive agent, which was commonly used in the 1970's and 80's for blood pressure control. Its use at
- Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies
Cochrane Systematic Reviews, 10-May-2018
Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate
- Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Cochrane Systematic Reviews, 25-Nov-2015
Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed and treated psychiatric disorders in childhood. Typically, children with ADHD find it difficult to pay attention, they are hyperactive and impulsive.
- Methylphenidate for children and adolescents with autism spectrum disorder
Cochrane Systematic Reviews, 21-Nov-2017
Children with autistic spectrum disorder (ASD) frequently present with inattention, impulsivity and hyperactivity, which are the cardinal symptoms of attention deficit hyperactivity disorder (ADHD). The effectiveness of methylphenidate, a commonly used AD
- Methylxanthine treatment for apnoea in preterm infants
Cochrane Systematic Reviews, 25-Feb-2013
Recurrent apnoea is common in preterm infants, particularly at very early gestational ages. These episodes of ineffective breathing can lead to hypoxaemia and bradycardia that may be severe enough to require the use of positive pressure ventilation. Methy
- Methylxanthines for exacerbations of chronic obstructive pulmonary disease
Cochrane Systematic Reviews, 22-Apr-2003
Most international guidelines currently recommend methylxanthines (e.g., theophylline, aminophylline) for severe exacerbations of chronic obstructive pulmonary disease (COPD), yet clinical trials underlying this recommendation have been small and underpow
- Methylxanthines for prolonged non-specific cough in children
Cochrane Systematic Reviews, 8-Nov-2010
Non-specific cough is defined as non-productive cough in the absence of identifiable respiratory disease or known aetiology. It is commonly seen in paediatric practice. These children are treated with a variety of therapies including a variety of asthma m
